Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Cohen-Kaminsky (Le Kremlin-Bicêtre, France), S. Sherbo (Haifa, Israel), Z. Wang (Haifa, Israel), E. Jutant (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), B. Girerd (Le Kremlin-Bicêtre, France), E. Lau (Le Kremlin-Bicêtre, France), L. Becquemont (Le Kremlin-Bicêtre, France), Y. Broza (Haifa, Israel), H. Haick (Haifa, Israel), M. Humbert (Le Kremlin-Bicêtre, France). Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). 3549

Member's Comments

No comment yet.

Related content which might interest you: Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Involvement of the pulmonary micro-vasculature in chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Pulmonary artery pulse pressure in chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Is there a fixed relationship between the mean and systolic pulmonary artery pressures in idiopathic pulmonary arterial hypertension (IPAH) and proximal chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2009 - Pulmonary embolism Year: 2009 Chronic thromboembolic pulmonary hypertension (CTEPH) and beyond Source: Annual Congress 2011 - Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Pulmonary Hypertension in the Clinic Grand Round - an interactive session Year: 2011 Pulmonary hypertension in patients with COPD Source: Eur Respir Mon 2012; 57: 138-147 Year: 2012 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) in patients after pulmonary embolism Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Platelets and pulmonary arterial hypertension (PAH) Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 637-648 Year: 2004 Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 27s Year: 2002